Ascendiant Capital Markets Predicts IGC Pharma FY2026 Earnings

IGC Pharma, Inc. (NYSEAMERICAN:IGC) – Equities researchers at Ascendiant Capital Markets issued their FY2026 earnings estimates for shares of IGC Pharma in a research note issued on Tuesday, August 25th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will earn ($0.10) per share for the year. Ascendiant Capital Markets has a “Buy” rating and a $5.50 price objective on the stock. The consensus estimate for IGC Pharma’s current full-year earnings is ($0.10) per share. Ascendiant Capital Markets also issued estimates for IGC Pharma’s FY2027 earnings at ($0.08) EPS.

IGC Pharma Stock Down 3.5%

Shares of NYSEAMERICAN:IGC opened at $0.30 on Monday. IGC Pharma has a 52-week low of $0.23 and a 52-week high of $0.47. The stock has a market cap of $30.93 million, a P/E ratio of -4.27 and a beta of 0.45. The business’s 50 day moving average is $0.27 and its 200 day moving average is $0.28. The company has a quick ratio of 0.19, a current ratio of 0.39 and a debt-to-equity ratio of 0.02.

IGC Pharma (NYSEAMERICAN:IGC) last issued its earnings results on Friday, August 14th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $0.27 million for the quarter.

Institutional Investors Weigh In On IGC Pharma

Several hedge funds have recently made changes to their positions in IGC. State Street Corp lifted its stake in IGC Pharma by 25.3% in the fourth quarter. State Street Corp now owns 200,799 shares of the company’s stock worth $57,000 after acquiring an additional 40,592 shares during the period. Virtu Financial LLC increased its position in IGC Pharma by 91.0% during the 3rd quarter. Virtu Financial LLC now owns 89,546 shares of the company’s stock valued at $37,000 after purchasing an additional 42,654 shares during the period. Finally, Citadel Advisors LLC increased its position in IGC Pharma by 131.7% during the 3rd quarter. Citadel Advisors LLC now owns 627,840 shares of the company’s stock valued at $262,000 after purchasing an additional 356,874 shares during the period. 3.87% of the stock is currently owned by hedge funds and other institutional investors.

About IGC Pharma

IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc and changed its name to IGC Pharma, Inc in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.